MétaCan
Menu
Back to cohort
Record W4363678756 · doi:10.1186/s10194-023-01573-6

European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 1: amitriptyline

2023· review· en· W4363678756 on OpenAlexaff
Christian Lampl, Jan Versijpt, Faisal Mohammad Amin, Christina Deligianni, Raquel Gil‐Gouveia, Tanvir Jassal, Antoinette MaassenVanDenBrink, Raffaele Ornello, Jakob Paungarttner, Margarita Sánchez del Río, Uwe Reuter, Derya Uludüz, Tessa de Vries, Dena Zeraatkar, Simona Sacco

Bibliographic record

VenueThe Journal of Headache and Pain · 2023
Typereview
Languageen
FieldMedicine
TopicMigraine and Headache Studies
Canadian institutionsMcMaster UniversityImpact
FundersServierLeids Universitair Medisch CentrumUniversiteit Leiden
KeywordsMedicineAmitriptylineMigraineDiscontinuationPlaceboAdverse effectRandomized controlled trialRelative riskInternal medicineMeta-analysisAnesthesiaConfidence intervalAlternative medicine

Abstract

fetched live from OpenAlex

OBJECTIVE: The aim of this paper is to critically re-appraise the published trials assessing amitriptyline for migraine prophylaxis. METHODS: We report our methods and results following the Preferred Reporting Items for Systematic Reviews (PRISMA), by searching MEDLINE, EMBASE, Cochrane CENTRAL, and ClinicalTrials.gov for randomized trials of pharmacologic treatments for migraine prophylaxis. We included randomized trials that compared amitriptyline with placebo for migraine prophylaxis in adults. Our outcomes of interest were informed by the Outcome Set for preventive intervention trials in chronic and episodic migraine (COSMIG) and include the proportion of patients who experience a 50% or more reduction in migraine days per month, migraine days per month, and adverse events leading to discontinuation. We assessed risk of bias by using a modified Cochrane RoB 2.0 tool and the certainty of evidence by using the GRADE approach. RESULTS: Our search yielded 10.826 unique records, of which three trials (n = 622) were eligible for data synthesis and analysis. We found moderate certainty evidence that amitriptyline increases the proportion of patients who experience a 50% or more reduction in monthly migraine days, compared to placebo (relative risk: 1.60 (95% CI 1.17 to 2.19); absolute risk difference: 165 more per 1,000 (95% CI 47 more to 327 more). We found moderate certainty evidence that amitriptyline increases the proportion of patients who discontinue due to adverse events compared to placebo (risk difference: 0.05 (95% CI 0.01 to 0.10); absolute risk difference: 50 more per 1,000 (95% CI 10 more to 100 more). CONCLUSIONS: Our meta-analysis showed that amitriptyline may have a prophylactic role in migraine patients, however these results are far from robust. This warrants further large-scale research to evaluate the role of amitriptyline in migraine prevention.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.184
metaresearch head score (Gemma)0.358
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Meta-epidemiology (broad)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.996
Threshold uncertainty score0.972

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1840.358
Meta-epidemiology (narrow)0.0040.002
Meta-epidemiology (broad)0.0220.031
Bibliometrics0.0160.008
Science and technology studies0.0010.003
Scholarly communication0.0060.003
Open science0.0040.003
Research integrity0.0050.003
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.254
GPT teacher head0.456
Teacher spread0.202 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations41
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of Headache and PainSame topicMigraine and Headache StudiesFrench-language works237,207